Overview

EPO906 Plus Radiation Therapy for the Treatment of Cancer Patients

Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the safety of the drug EPO906 that could shrink tumors when used with radiation therapy in cancer patients.
Phase:
Phase 1
Details
Lead Sponsor:
Sidney Kimmel Cancer Center at Thomas Jefferson University
Thomas Jefferson University
Collaborator:
Novartis Pharmaceuticals
Treatments:
Epothilone B
Epothilones